NASDAQ:EDIT

Editas Medicine Stock Predictions

etoro logo Buy EDIT
*Your capital is at risk
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

EDIT Prediction Chart

EDIT Predictions History

Latest community submissions for EDIT.
Predictor Target Session Target Price Result Direction Accuracy Score
Nathan Smith Nathan Smith @NathanSmith.132703
May 19, 2025 Bullish $1.49 X 0
Feb 29, 2024 $10.81 -2.32% $10.06 V 92.51% 1
Feb 29, 2024 $10.91 -1.45% $10.06 V 91.55% 1
Feb 29, 2024 $13.00 +46.73% $10.06 V 70.78% 0
Aug 24, 2021 $67.00 +3.52% $64.72 X 96.48% 0
Aug 23, 2021 $62.32 -4.65% $65.36 X 95.35% 1
JS JS Pro
Aug 23, 2021 $61.69 -5.62% $65.36 X 94.38% 1
JS JS Pro
Feb 16, 2021 $59.12 +4.73% $56.45 X 95.27% 0
Feb 16, 2021 Bullish $56.45 X 0
Feb 16, 2021 Bearish $56.45 X 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for EDIT with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT EDITAS MEDICINE, INC
Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE